TIRZ
GLP-1T is a novel dual-agonist peptide that activates both the GLP-1 and GIP receptors. This dual action makes it a subject of intense research for its superior effects on glycemic control and weight loss compared to single-agonist peptides.
Price range: $108.00 through $258.00
The information provided on this page is intended solely as a general summary. It does not encompass all potential research applications, handling procedures, safety precautions, interactions, or observed effects. These products are supplied strictly for laboratory and research purposes only. They are not intended for human consumption, medical use, veterinary use, or diagnostic purposes. This information must not be considered a substitute for professional expertise, judgment, or regulatory guidance.
Money Back Guarantee
Guaranteed Quality
Fast Shipping
10+ Years Experience
Frequently Bought Together
SEQUENCE/FORMULA
MOLECULAR WEIGHT
PUBCHEM CID
- Investigating its efficacy for glycemic control in adults with type 2 diabetes. (Marketed as Mounjaro®)
- Studying its use for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity. (Marketed as Zepbound®)
- Analyzing its effects on cardiovascular outcomes, including the risk of heart attack, stroke, and cardiovascular death.
- Exploring its potential for treating related metabolic conditions such as non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF).
- Tirzepitide is a novel, first-in-class dual GLP-1 and GIP receptor agonist. This means it activates two different gut hormone pathways involved in metabolism.
- GLP-1 (Glucagon-like peptide-1) Receptor Agonism: This action increases insulin secretion in response to high blood sugar, suppresses the hormone glucagon, slows down stomach emptying, and acts on the brain to reduce appetite and increase feelings of fullness (satiety).
- GIP (Glucose-dependent insulinotropic polypeptide) Receptor Agonism: This action also enhances insulin secretion and is believed to have additional beneficial effects on how the body processes sugar and fat, potentially improving insulin sensitivity and reducing fat accumulation.
- By targeting both pathways simultaneously, it produces a synergistic and more potent effect on blood sugar control and weight loss compared to activating only the GLP-1 pathway.
- Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine, 385(6), 503-515.
- Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 387(3), 205-216.
- Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14.
- Faris, M., et al. (2021). Tirzepatide: a new generation of dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 30(5), 453-464.